Hi readers, Welcome to the September issue of Pharmafocus! We’ve been experiencing record temperatures here in the UK, and across Europe – we hope you’ve been coping with the heat and enjoying your summer, wherever you are in the world. There have been some major changes across the health and pharma landscape since our last issue. For one, the WHO activated its highest alert for the growing monkeypox outbreak on 23 July – declaring the virus a global health emergency. The UK is currently waiting for 100,000 vaccines to treat monkeypox, but, according to the UKHSA, only 50,000 have been received thus far due to supply issues.
On a more positive note, HealthTrackRx has developed a monkeypoxspecific PCR test, with next-day results. This will be available to thousands of customers across the US, to combat the recent surge in cases across the country. Read more about this on page 8.
In this issue, we also delve into some exciting new developments in technology. Cognito Therapeutics has unveiled new data showing that six months’ use of its digital therapeutic could potentially reduce the rate of atrophy within the brain’s white matter in patients with Alzheimer’s. You can check out the full story in our digital news section, on page 12.
That’s it from us! We hope you enjoy reading through our latest issue as much as we enjoyed putting it together.
Pop open a cold drink, sit back in the shade, and enjoy Pharmafocus September!